The results showed that inhibiting CD133 significantly increased the sensitivity of LoVo/ADR cells to DOX (Fig. 6a), and the tumour size and tumour weight showed similar results, as expected (Fig. 6c). This evidence concerns the gene PROM1 and neoplasm.